Sacubitril/valsartan cost-effective for HFREF patients
Switching to sacubitril/valsartan is a cost-effective treatment option for patients with heart failure with reduced ejection fraction (HFREF), a recent Australia study has found.
Sacubitril/valsartan cost-effective for HFREF patients
04 Oct 2020
